Answer
It is licensed to prevent serious RSV lower respiratory tract disease requiring hospitalisation in specified high-risk young children.
Sources for this answer
- Synagis 50 mg/0.5 ml solution for injection — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.